Numerous clinical studies have identified specific targets, such as mesothelin (MSLN), CD133, Prostate stem cell antigen (PSCA), Claudin 18.2, and HER-2, for CAR-T immunotherapy in pancreatic cancer (PCA). Here, MSLN is linked to posterior cortical atrophy.